The DEA Marijuana Rescheduling Hearing: What to Know

The DEA Hearing That Could Reshape Cannabis Law Started June 29. Here’s What’s Actually Happening.

A federal hearing now underway will help decide whether marijuana moves off Schedule I. The process has drawn intense scrutiny from every side. Here’s a plain-spoken, neutral breakdown of what’s going on, and why hemp’s separate legal status matters more than ever for consumers.

What the Hearing Is, and What It Isn’t

If you follow cannabis news even casually, you’ve probably seen headlines about a major federal hearing. The coverage has been heated, so let’s slow down and lay out the facts as neutrally as possible, because this is a story where the details matter more than the outrage.

On June 29, an administrative law judge began hearing arguments on whether marijuana should be moved from Schedule I of the Controlled Substances Act (the most restrictive category, reserved for drugs the government considers to have no accepted medical use) to Schedule III (a far less restrictive category). The hearing is scheduled to run through July 15, with a recess around the Fourth of July holiday.

A few important clarifications up front. This hearing concerns marijuana, the state-regulated cannabis sold in dispensaries, not the hemp-derived products that Crafty makes. Those are governed by entirely different federal law. We’ll come back to why that distinction matters. The hearing also won’t produce a binding verdict; at the end, the judge issues a recommendation, and federal agencies then decide whether and when to act on it. There’s no deadline forcing a final decision.

The scope has also narrowed. Because medical cannabis and FDA-approved cannabis products already moved to Schedule III earlier in the year, the current hearing is weighing only whether the rest of the plant should follow.

This is a hearing about marijuana’s federal classification, not about hemp-derived products like Crafty’s. The two operate under separate laws, which is exactly why the distinction is worth understanding.

Why has the coverage been so intense? Largely because of who was, and wasn’t, invited to participate, and because of how the process is being run. Here’s where the controversy lives.

Who’s in the Room, and the States on the List

The DEA released its roster of designated participants in mid-June. Seven outside parties were granted a seat, and according to extensive reporting, all seven oppose rescheduling. No reform supporter made the final list.

The participants include the National Drug & Alcohol Screening Association, the Tennessee Bureau of Investigation, the advocacy group Smart Approaches to Marijuana, the group DUID Victim Voices, two individual physicians, and four states: Nebraska, Idaho, Indiana, and Louisiana. Each is scheduled for its own day across the hearing’s run.

Those four states are worth a closer look, because their cannabis laws help explain why they’re at the table. They represent some of the more restrictive cannabis policy environments in the country:

Nebraska: Voters approved medical cannabis ballot measures in 2024, but the state has no adult-use market, and implementation of even the medical program has been contested. Recreational marijuana remains illegal.

Idaho: One of the strictest states in the nation. No medical marijuana program and no adult-use market. Idaho has actively resisted loosening its cannabis laws.

Indiana: No comprehensive medical marijuana program and no adult-use market. Cannabis remains broadly prohibited under state law.

Louisiana: Has a medical marijuana program, but no adult-use market, and the state has taken a notably cautious posture on hemp and cannabis regulation more broadly.

Tennessee, represented at the hearing by its Bureau of Investigation, similarly has no adult-use market and only a very limited low-THC medical framework. The throughline is that the states seated for the hearing are, by and large, those that have kept the tightest cannabis restrictions.

The reason participation was limited comes down to a legal standard: the DEA required participants to be “adversely affected or aggrieved” by the proposed rule. Reform groups argued that, by that logic, supporters were defined out of the room.

Several well-known organizations applied and were not seated, including long-established reform groups and a major licensed cannabis distributor. Supporters have noted that an earlier version of this process, conducted under the prior administration, seated a larger and more mixed group of roughly two dozen participants that included both supporters and opponents. The proposed rule itself didn’t change between then and now; the administration did.

It’s also notable that public comment on the proposed rule ran heavily in favor of reform. Independent researchers analyzing the roughly 43,000 public comments found that the overwhelming majority supported the Schedule III move or wanted broader reform. Supporters argue that perspective won’t be represented in the hearing room.

There’s genuine disagreement about whether the process is fair, and reasonable people land in different places. What’s not in dispute is that this is an unusual proceeding being watched closely by courts, businesses, and consumers alike. For broader context on how the federal hemp and cannabis landscape is shifting: Medicare Hemp Coverage Pilot: CMS Allows Physician-Furnished Hemp Products Up to $500 Per Year.

What This Means for You, the Consumer

Here’s the advice column finish, because a story this tangled deserves a clear, practical takeaway.

First, the honest part: nobody knows how this ends, and anyone telling you they do is guessing. The judge could recommend Schedule III, a different schedule, or no change at all. Federal agencies aren’t bound by the recommendation and face no deadline to act. Courts are already involved, with multiple legal challenges filed. This will play out over months, possibly longer. If you take one thing from the coverage, let it be patience rather than certainty.

Second, the part that actually affects your daily life: this fight is about state-regulated marijuana’s federal classification. It does not change the legal status of the hemp-derived Delta-9 THC products that Crafty makes. Crafty products are produced under the framework established by the federal Farm Bill, which legalized hemp and hemp-derived cannabinoids containing less than 0.3% Delta-9 THC by dry weight. That’s a separate legal lane from the marijuana rescheduling question, and it’s part of why hemp-derived products have remained broadly available across most of the country while marijuana law has stayed in limbo.

This is the bigger lesson for consumers in an uncertain regulatory moment: clarity and transparency are worth seeking out. When the legal landscape is complicated, you want products that are straightforward about what they are. Every Crafty THC gummy contains a clearly labeled 5mg of Delta-9 THC. Every Crafty THC beverage contains 10mg. Every batch is third-party lab tested, with Certificates of Analysis available to anyone who wants to verify exactly what’s inside. In a world of regulatory gray areas, that kind of transparency isn’t a luxury. It’s the whole point.

Hemp and cannabis law has always moved in fits and starts, and understanding that history helps make sense of the present moment. If you’d like the longer view, a few of our recent pieces:

→ 5 Strange and Charming Tales From the History of Cannabis

→ Morocco’s Rif Mountains: The Centuries-Old Heritage of Hash

→ World Cup Cannabis Guide: How Fans Can Celebrate Legally by State

And for the everyday question that no federal hearing will answer for you: Can You Drive the Morning After Weed? New Study Results for Crafty Consumers.

Federal cannabis policy may stay uncertain for a while. What you can count on is what’s on the label. Clear dose, lab-tested, hemp-derived, and legal under the Farm Bill.

20% Off Storewide

Use code FREEDOM20 at checkout for 20% off your entire order.

Low-dose. Lab-tested. Farm Bill-compliant. Clarity you can count on.

Shop All Products
Safety note: This article is for informational and educational purposes only and is not legal advice. It summarizes ongoing federal proceedings and policy debates from publicly reported sources; details may change as the process unfolds. Crafty products are derived from Farm Bill-compliant hemp containing less than 0.3% Delta-9 THC by dry weight and are distinct from state-regulated marijuana. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Do not drive while impaired. Do not mix THC with alcohol. Must be 21+ to purchase.

Recommended Posts

No comment yet, add your voice below!


Add a Comment

Your email address will not be published. Required fields are marked *